Defining the combined benefit of intermittent preventive malaria treatment in pregnancy

Published: 8 July 2020 03:27

WHO  has  included  intermittent  preventive  treatment  in  pregnancy  (IPTp)  with  sulfadoxine-pyrimethamine  as  an  important  malaria  intervention  since  2012.1  Although  other candidate therapies remain under investigation and despite  waning  sulfadoxine-pyrimethamine  antimalarial  efficacy  due  to  increasing  parasite  resistance,  IPTp  with  sulfadoxine-pyrimethamine  remains  a  key  component  of   the   management   of   pregnant   women   in   malaria-endemic areas. In areas of high-grade parasite resistance, the   use   of   IPTp   with   sulfadoxine-pyrimethamine   is   associated with improved birth weight, suggesting that there are benefits of beyond antimalarial efficacy.

WHO  has  included  intermittent  preventive  treatment  in  pregnancy  (IPTp)  with  sulfadoxine-pyrimethamine  as  an  important  malaria  intervention  since  2012.1  Although  other candidate therapies remain under investigation and despite  waning  sulfadoxine-pyrimethamine  antimalarial  efficacy  due  to  increasing  parasite  resistance,  IPTp  with  sulfadoxine-pyrimethamine  remains  a  key  component  of   the   management   of   pregnant   women   in   malaria-endemic areas. In areas of high-grade parasite resistance, the   use   of   IPTp   with   sulfadoxine-pyrimethamine   is   associated with improved birth weight, suggesting that there are benefits of beyond antimalarial efficacy.